|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2006
Appropriateness and delay to initiate therapy in ventilator-associated pneumonia
1 Pulmonary and Critical Care Divisions, Dept of Medicine, Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, and 2 Critical Care Division, Policlínico Alejandro Posadas, Haedo, Provincia de Buenos Aires, Argentina. 3 Dept of Medicine and Pulmonary and Critical Care Division, Winthrop University Hospital, Mineola, NY, USA.
CORRESPONDENCE: C. M. Luna, Acevedo 1070, Banfield, 1828, Buenos Aires, Argentina. Fax: 54 1142026068. E-mail: cymluna{at}fmed.uba.ar
Keywords: Adequate therapy, antimicrobials, delayed therapy, nosocomial pneumonia, outcome, resistant pathogens
Received: April 23, 2005
Accepted August 12, 2005
Inappropriate therapy (IT) and delayed initiation of appropriate therapy (DIAT) result in inadequate therapy in patients with ventilator-associated pneumonia (VAP). The aim of the current study was to assess the impact of DIAT in VAP. A total of 76 mechanically ventilated patients with bacteriologically confirmed VAP were prospectively evaluated in the intensive care unit of six hospitals in Buenos Aires, Argentina.
Appropriate therapy was defined as coverage of all the identified pathogens by the antimicrobial therapy administered at the time of VAP clinical diagnosis. The clinical pulmonary infection score was measured during the 3 days before, at the onset and during the days which followed the onset of VAP. A total of 24 patients received adequate therapy; mortality was 29.2%. The remaining 52 patients received either IT (n = 16) or DIAT (n = 36); the mortality was 63.5% combined, and 75.0 and 58.3% for IT and DIAT, respectively (statistically significant compared with adequate therapy).
Inappropriate therapy and delayed initiation of appropriate therapy increased the mortality of ventilator-associated pneumonia. Patients with inappropriate therapy and/or delayed initiation of appropriate therapy had a more gradual increase in clinical pulmonary infection score than those receiving adequate therapy, and this increase was found to occur prior to the time of the clinical diagnosis.
In conclusion, these findings might provide the rationale for a trial of earlier initiation of therapy, based on clinical grounds in an effort to improve the outcome of patients with ventilator-associated pneumonia.
This article has been cited by other articles:
|
|
 |
|
  D. Plachouras, M. Karvanen, L. E. Friberg, E. Papadomichelakis, A. Antoniadou, I. Tsangaris, I. Karaiskos, G. Poulakou, F. Kontopidou, A. Armaganidis, et al. Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria Antimicrob. Agents Chemother., August 1, 2009; 53(8): 3430 - 3436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Grossman Hospital-Acquired and Ventilator-Associated Pneumonia ACCP Pulmonary Med Brd Rev, January 1, 2009; 25(0): 391 - 400. [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Rosbolt, E. S. Sterling, and B. G. Fahy The Utility of the Clinical Pulmonary Infection Score J Intensive Care Med, January 1, 2009; 24(1): 26 - 34. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Lisboa, E. Diaz, M. Sa-Borges, A. Socias, J. Sole-Violan, A. Rodriguez, and J. Rello The Ventilator-Associated Pneumonia PIRO Score: A Tool for Predicting ICU Mortality and Health-Care Resources Use in Ventilator-Associated Pneumonia Chest, December 1, 2008; 134(6): 1208 - 1216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kothe, T. Bauer, R. Marre, N. Suttorp, T. Welte, K. Dalhoff, and the Competence Network for Community-Acquired Pneu Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment Eur. Respir. J., July 1, 2008; 32(1): 139 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Visscher, E. M. Kruisheer, C. A. M. Schurink, P. J. F. Lucas, and M. J. M. Bonten Predicting pathogens causing ventilator-associated pneumonia using a Bayesian network model J. Antimicrob. Chemother., July 1, 2008; 62(1): 184 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Parkins, D. M. Sabuda, S. Elsayed, and K. B. Laupland Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections J. Antimicrob. Chemother., September 1, 2007; 60(3): 613 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Curcio and F. Fernandez Acinetobacter spp. susceptibility to tigecycline: a worldwide perspective J. Antimicrob. Chemother., August 1, 2007; 60(2): 449 - 450. [Full Text] [PDF]
|
|
|
|
|
|
C. M. Luna, S. Baquero, S. Gando, J. R. Patron, J. G. Morato, O. Sibila, R. Absi, A. Famiglietti, C. A. Vay, F. Von Stecher, et al. Experimental Severe Pseudomonas aeruginosa Pneumonia and Antibiotic Therapy in Piglets Receiving Mechanical Ventilation Chest, August 1, 2007; 132(2): 523 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Curcio, F. Fernandez, R. N. Jones, M. J. Ferraro, L. B. Reller, P. C. Schreckenberger, and H. S. Sader Tigecycline Disk Diffusion Breakpoints of Acinetobacter spp.: a Clinical Point of View J. Clin. Microbiol., June 1, 2007; 45(6): 2095 - 2096. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |